Browse > Article

Institutional Review Board (IRB) Mutual Recognition Program and Its Feasibility in Korea  

Cheong, Hye-Rim (Office of Human Research Protection, Catholic Medical Center, The Catholic University of Korea)
Yim, Hyeon-Woo (Department of preventive medicine, College of Medicine, The Catholic University of Korea)
Choe, Byung-In (Office of Human Research Protection, Catholic Medical Center, The Catholic University of Korea)
Kim, Yeong-In (Department of Neurology, Seoul St. Mary's Hospital, The Catholic University of Korea)
Publication Information
Journal of Korean Society for Clinical Pharmacology and Therapeutics / v.19, no.2, 2011 , pp. 152-165 More about this Journal
Abstract
Background: The use of Cooperative Institutional Review Board (Co-IRB) has become subject to continuous discussion. As a result, leading mainly by the Korea Association of Institutional Review Boards (KAIRB), "IRB mutual recognition program (MR-IRB)" was proposed. However operational methods of the program are still controversial. The object of this research is to examine domestically feasible scope and operation methods of MR-IRB by conducting survey. Methods: 71 survey data was collected from chairman or specialist of each IRB and 29 IRB members of one institution running Central IRB was included. Results: 76.5 % of respondents selected phase 3 multi-national, multi-center clinical Sponsor Initiated Trial as a suitable subject of MR-IRB, but only 50 % supported Investigator initiated trials, and answered early-stage clinical trials such as phase 1 clinical trials or biological agent trials are unsuitable due to relatively insufficient knowledge on risk level. In order to operate MR-IRB, standardized review criteria and agreement of institutions in building mutual trust is essential. Also it was learned from the survey that the most desirable way to adopt MR-IRB is to be initiated by the representing organization such as KAIRB based on mutual trust from institutional agreement. Conclusion: MR-IRB was recognized as one of Co-IRB. A suitable subjects of MR-IRB were preferred the phase 3 multi-national, multi-center clinical sponsor initiated trials to all kinds of clinical trials. This study suggests that based on real operation experience from MR-IRB pilot study, further study should be conducted to analyze pros and cons of MR-IRB and identify domestically eligible model to facilitate MR-IRB.
Keywords
Cooperative institutional review board; IRB mutual recognition program; Central institutional review board (CIRB);
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Shin HY. Improving the Efficiency of IRB through Joint IRB in Multicenter Clinical Trials in Korea. Kor J Clin Pharmacol Ther, 2009;17(1):44-50. (Korean)
2 U.S. Food and Drug Administration, Guidance for industry: using a centralized IRB review process in multicenter clinical trials. 2006.
3 공동 심사위원회 운영 가이드라인. 식품의약품안전청, 2010.
4 Oh JM, Recommendation for strengthening function of institutional review board and activating centralized review system. Sookmyung Women's University, 2009. (Korean)
5 Lee SM, Kim SH, Kim HJ, Kim OJ, Bae KS, Park BJ. Current Status of the Joint Institutional Review Boards in Foreign Countries and Suggestion for Operating in Korea. Kor J Clin Pharmacol Ther, 2006;14(2):142-150. (Korean)
6 Ravina B, Deuel L, Siderowf A, Dorsey ER. Local institutional review board (IRB) review of a multicenter trial: local costs without local context. Ann Neurol, 2010;67(2):258-260.   DOI   ScienceOn
7 FERCAP web site, http://www.fercap-sidcer.org
8 AAHRPP web site, http://www.aahrpp.org